What sermorelin is
Sermorelin is a 29-amino-acid analogue of the active amino-terminal portion of human growth hormone-releasing hormone. It stimulates a functioning pituitary to release growth hormone rather than replacing growth hormone directly.
The United States previously approved sermorelin acetate as Geref for pediatric growth-hormone deficiency and diagnostic use. The approved product was withdrawn from the market at the applicant’s request in 2009; FDA later recorded that it was not withdrawn for safety or effectiveness reasons.[1][2]
Historical approval is not current product approval
Geref’s historical approval establishes that a defined sermorelin product once met FDA’s standard for its narrow labelled uses. It does not make today’s compounded injections, blends, online vials, anti-aging services, or wellness protocols FDA-approved. No currently marketed U.S. Geref product was identified in the review.
An FDA substance identifier or orphan-drug record documents identity or history; it is not proof that a current finished product is approved.[3]
The human evidence is narrow and dated
A review of the historical pediatric program reported that sermorelin could provoke growth-hormone release and that limited data showed increased height velocity in some prepubertal children with idiopathic growth-hormone deficiency. It also noted that final adult-height effects were undetermined and that direct comparison with somatropin was lacking.[4]
Those pediatric and diagnostic findings do not demonstrate better sleep, body composition, energy, muscle, recovery, cognition, or longevity in healthy adults. The popular anti-aging use has no comparable controlled outcome evidence.
Safety evidence does not transfer to current vials
Historical short-term reports included injection-site pain, flushing, headache, nausea, dizziness, sleepiness, and hypersensitivity. The limited pediatric data do not establish the safety of long-term adult use, use in people without deficiency, combination with other secretagogues, or products made to different specifications.
Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing.[5] FDA has documented a nationwide sterile-compounding recall that included sermorelin and sermorelin/GHRP blends, illustrating that product-quality risk is separate from the molecule’s pharmacology.[6]
Sport and protocol status
Growth-hormone-releasing factors are prohibited under the current World Anti-Doping Agency list.[7] Because no current approved product, healthy-adult indication, or general regimen exists, Teloryx withholds sermorelin dosing, reconstitution, anti-aging, and combination protocols.